Skip to main content
Improve Medical Instruments CO., Ltd. logo

Improve Medical Instruments CO., Ltd. — Investor Relations & Filings

Ticker · 300030 ISIN · CNE100000JL3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,954 across all filing types
Latest filing 2022-08-25 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300030

About Improve Medical Instruments CO., Ltd.

https://www.improve-medical.com

Improve Medical Instruments CO., Ltd. focuses on the development, production, and distribution of clinical laboratory and nursing solutions. The core product range includes evacuated blood collection systems, specimen collection and transport media, and laboratory automation equipment. The company also provides medical imaging components and point-of-care testing (POCT) systems. By integrating research and development with advanced manufacturing, the organization supports clinical diagnostics and patient care through high-precision tools designed for healthcare facilities and research laboratories. Its offerings are characterized by a commitment to diagnostic safety and efficiency across global markets.

Recent filings

Filing Released Lang Actions
独立董事工作制度2022.08
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System'. It details the rules, qualifications, duties, nomination, election, and responsibilities of independent directors in the company. It references relevant laws and regulations such as the Company Law, Securities Law, and rules from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The content is about governance practices, internal rules, and board structure related to independent directors. There is no financial data, audit information, or report publication mentioned. The document is a governance-related policy document rather than a report or announcement. Therefore, the most appropriate classification is Governance Information (CGR).
2022-08-25 Chinese
董事、监事和高级管理人员所持公司股份及其变动管理制度2022.08
Director's Dealing Classification · 95% confidence The document is a detailed management system outlining the rules and procedures for the holding and trading of company shares by directors, supervisors, and senior management personnel. It includes legal references, disclosure requirements, lock-up periods, and reporting obligations related to insider trading and shareholding changes. The content focuses on governance and compliance related to insider share transactions and management conduct rather than financial results, audit opinions, or shareholder meeting materials. It is not a report of financial performance, earnings, or capital changes, nor is it a simple announcement or certification. The document fits best under the category that covers internal rules and governance practices related to board and management shareholding and conduct. Therefore, the appropriate classification is Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives and related management rules.
2022-08-25 Chinese
关于披露2022年半年度报告及摘要的提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (405 characters) about the disclosure of the company's 2022 half-year (semi-annual) report and its summary. It states that the report was approved by the board and published on a regulatory website. The document itself does not contain the actual financial data or the report content but serves as a notice to investors to review the full report elsewhere. According to the 'Menu vs Meal' rule, such a brief announcement about the report's availability is classified as a Report Publication Announcement (RPA), not the report itself (which would be an Interim/Quarterly Report IR).
2022-08-25 Chinese
2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 半年度报告摘要' which translates to '2022 Half-Year Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, total assets, and shareholder information for the half-year period. The presence of substantive financial data and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is 2354 characters, which is relatively short but contains actual financial data, not just an announcement or summary without data. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-25 Chinese
董事会议事规则2022.08
Governance Information Classification · 95% confidence The document is titled "董事会议事规则" which translates to "Rules of Procedure for the Board of Directors" of 阳普医疗科技股份有限公司. It details the composition, responsibilities, meeting procedures, voting rules, and record-keeping of the company's board of directors. There is no financial data, no report of financial results, no announcement of voting results, no management changes, no legal proceedings, no capital updates, and no other regulatory filings. The content is focused on governance practices and internal rules of the board. Therefore, the document fits the category of Governance Information (CGR). The document length is over 7,000 characters, indicating it is a full document, not a brief announcement or certification. Hence, the classification is CGR with high confidence.
2022-08-25 Chinese
2022年半年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 90% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the half-year period of 2022 by 阳普医疗科技股份有限公司. It contains specific financial data such as beginning balances, amounts occupied, interest, repayments, and ending balances for various related parties and subsidiaries. The document is a financial summary for a half-year period but does not appear to be a full interim or quarterly report with comprehensive financial statements or analysis. It is more of a specific financial disclosure related to related party transactions and fund usage. Given the nature and content, it fits best under Regulatory Filings (RNS) as a specialized disclosure rather than a full Interim Report (IR) or Annual Report (10-K). The document length is short (2163 characters), and it is a detailed disclosure rather than an announcement or certification. Therefore, the classification is RNS with high confidence.
2022-08-25 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.